New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
06:35 EDTILMN, WXWuXi PharmaTech purchases Illumina HiSeq X Ten Sequencing System
Illumina (LMN) and WuXi PharmaTech (WX) announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system. This new investment will enable WuXi’s clinical genomic services to expand from the current target panel, exome, and transcriptome scale sequencing to population genome scale sequencing. It puts the world’s most advanced gene sequencing capability in the hands of the leading pharmaceutical R&D services company in the Asia Pacific region. The WuXi Genome Center meets international clinical standards and is the only CLIA-certified clinical genomics lab in China. In addition to offering sequencing services, WuXi’s genomics lab also provides assay development, validation, and testing services.
News For WX;ILMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
06:34 EDTILMNObama to propose $215M for major medical program, CNBC says
Subscribe for More Information
January 28, 2015
09:22 EDTILMNIllumina price target raised to $230 from $200 at Wedbush
Subscribe for More Information
08:40 EDTILMNIllumina price target raised to $221 from $192 at Janney Capital
Subscribe for More Information
08:27 EDTILMNIllumina price target raised to $234 from $220 at BofA/Merrill
BofA/Merrill raised Buy rated Illumina's price target to $234 citing strong Q4 organic sales momentum.
07:59 EDTILMNIllumina price target raised to $225 from $195 at Leerink
Subscribe for More Information
January 27, 2015
16:09 EDTILMNIllumina sees FY15 non-GAAP EPS $3.12-$3.18, consensus $3.20
For FY15 the Company is projecting approximately 20% revenue growth, assuming current currency exchange rates, and non-GAAP EPS of $3.12-$3.18. These projections assume full year non-GAAP gross margin of approximately 73%, and a pro forma tax rate of approximately 28%.
16:08 EDTILMNIllumina reports Q4 non-GAAP EPS 87c, consensus 78c
Reports Q4 revenue $512M, consensus $507.65M.
January 23, 2015
15:46 EDTILMNPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
January 21, 2015
10:24 EDTILMNIllumina pulls back following State of the Union address
Shares of Illumina (ILMN) rose yesterday after a biotech industry website reported that President Obama might unveil a major new genomics project during his State of the Union address last night. That speculation was backed as a possibility by an analyst at Wells Fargo ahead of last night's address. In the speech, President Obama unveiled what he called his Precision Medicine Initiative, which relies on genomics to "deliver(s) the right treatment at the right time." Obama spent far more time, however, discussing economic growth and foreign relations than healthcare. Illumina shares are down 3% to $190.64 in early trading today.
January 20, 2015
13:45 EDTILMNIllumina rises as genomics project seen being announced in State of the Union
Subscribe for More Information
11:24 EDTILMNIllumina could see headline boost from U.S. genomics project, says Wells Fargo
After biotech industry publication BioCentury said Friday that the president may announce a new genomics project to sequence up to one million human genomes as part of his State of the Union speech tonight, Wells Fargo said that it believes such an announcement could be a headline catalyst for Illumina since it would mean the U.S. needs additional sequencing capacity. However, such a project would be long-term in nature, Wells Fargo cautioned, adding that such a plan would more likely support existing Illumina growth assumptions than push those forecasts up. Shares of Illumina are up 6% to $194.85 in morning trading ahead of tonight's speech by the president.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use